培美曲塞与铂类联合治疗难治性晚期乳腺癌疗效及药物副反应观察  

Observation on The Efficacy and Side Effects of Pemetrexed and Platinum in the Treatment of Refractory Advanced Breast Cancer

作　　者：余晶平 

机构地区：[1]福建省南平市建阳第一医院肿瘤内科,福建南平354200

出　　处：《中国卫生标准管理》2017年第28期70-72,共3页China Health Standard Management

摘　　要：目的探讨难治性晚期乳腺癌实施培美曲塞与铂类联合治疗的疗效及药物副反应状况。方法选择本科室2011年6月—2016年6月间难治性晚期乳腺癌患者58例进行观察研究,按患者用药方案分为顺铂组(n=29)和奥沙利铂组(n=29),顺铂组患者实施培美曲塞+顺铂治疗,奥沙利铂组患者实施培美曲塞+奥沙利铂治疗,分析总结两种用药方案的疗效及药物副反应状况。结果顺铂组患者治疗有效率、1年存活率较奥沙利铂组无明显差异(P>0.05),奥沙利铂组患者周围神经毒性、关节疼痛副作用发生率较顺铂组明显降低(P<0.05)。结论难治性晚期乳腺癌实施培美曲塞与铂类联合治疗疗效显著,药物副反应较轻,且培美曲塞与奥沙利铂联合用药不良反应更少。Objective To investigate the efficacy and side effects of pemetrexed combined with platinum in the treatment of refractory advanced breast cancer. Methods 58 patients from June 2011 to June 2016 in our department of refractory advanced breast cancer were studied, and according to the regimen were divided into cisplatin group （n=29） and oxaliplatin group（n=29）, the implementation of pemetrexed plus cisplatin in the treatment of patients with cisplatin group, and the implementation of pemetrexed plus oxaliplatin in the treatment of patients with oxaliplatin group. Analysis of effcacy and adverse drug reaction situation summed up the two kinds of medication. Results The effective rate, the 1 year survival rate in the cisplatin group were not signifcantly different from those in the oxaliplatin group （P 〉 0.05）. The incidence of peripheral nerve toxicity and joint pain in the oxaliplatin group was signifcantly lower than that in the cisplatin group （P 〈 0.05）. Conclusion Pemetrexed combined with platinum is effective in the treatment of refractory advanced breast cancer, with less side effects, and less adverse reactions of pemetrexed combined with oxaliplatin.

关 键 词：难治性晚期乳腺癌 培美曲塞 铂类 疗效 药物副反应 

分 类 号：R737[医药卫生—肿瘤]